How Greencross grew from one Townsville vet clinic into Australia's largest pet care group through 100+ acquisitions, and why TPG's exit has stalled since.
Greencross Limited (ASX: GXL) was Australia's largest integrated pet care company. It combined veterinary services (Greencross Vets) with specialty pet retail (Petbarn, City Farmers and Animates).
Greencross consolidated the fragmented Australian veterinary market, acquiring independent clinics at 3.5–4.5× EBIT while trading at far higher public multiples. In 2014 it merged with Mammoth Pet Holdings (Petbarn) and acquired City Farmers, transforming from a vet roll-up into an integrated vets-plus-retail platform.
Greencross was taken private by TPG Capital in March 2019 at $5.55 per share ($675m equity value). A 45% stake sold to AustralianSuper and HOOPP in 2022 valued the group at ~$3.5bn. TPG's planned ~$700m IPO was shelved in 2026 in favour of a ~$4bn trade sale to Coles, which collapsed in July 2026 after investor backlash. TPG is still seeking an exit.
Greencross listed in June 2007 at $1.00 per share. An IPO investor who held to the TPG takeover at $5.55 realised a 5.5× capital return, roughly 6× including dividends: about a 16% annual compound return over 12 years. Investors who bought at the 2016 peak above $9.00 lost around 40%.
September 2026, when this case study was first published. Figures and company status reflect information available at that date.
Greencross was founded in 1994 by Dr Glen Richards, a vet who grew up on a sheep and cattle station in rural Queensland. At 27, with ~$5,000 in the bank and backing from his parents, he bought the Currajong Veterinary Hospital in Townsville, a deal agreed by handshake over the phone from London.
The original business plan was written on a seven-day Trans-Siberian Express journey in late 1993. It set out a vision for a national network of veterinary hospitals. Within a decade Richards had five clinics and a pet store in Townsville, plus two veterinary hospitals in China.
In 2006 Richards adopted a disciplined corporate structure and joined forces with a team that had optioned 13 practices. Greencross listed on the ASX in June 2007 at $1.00 per share, raising ~$10m with 32 clinics and a ~$30m market cap: the first Australian vet group to go public.
Richards used a "franchise-like" support model: centralised buying, marketing and education, with clinical autonomy left at practice level. An employee share loan plan (2011) aligned staff with shareholders. At its peak the group ran:
Greencross made money from two sources: veterinary service fees and pet product retail sales. The vet division charged for consultations, vaccinations, surgery, dentistry, pathology, emergency care and cremation. The retail division sold pet food, accessories and grooming products through big-box stores. Both targeted the same customer, the "pet parent", in an ANZ addressable market estimated at $9.5bn.
The key differentiator was integration. By co-locating vet clinics inside or beside Petbarn stores, Greencross created a one-stop shop: a vet could recommend a diet or treatment and the owner could buy it on the spot. The model was established in the US and UK but new to Australia. The Healthy Pets Plus membership program and Petbarn's 1.1 million member "Friends for Life" loyalty program linked the two sides of the business and lifted spend per customer.
Acquisitions worked on two levels. Clinic acquisitions bought earnings cheaply (3.5–4.5× EBIT) and improved them through centralised purchasing, marketing and benchmarking. Acquired practices delivered like-for-like EBIT growth above 10% inside the network. The platform deals (Mammoth, City Farmers) added the retail layer: scale, a second revenue stream from the same customers, and the co-location strategy that defined the company.
Richards, a practising vet, sourced deals through his industry network and positioned Greencross as the succession solution for ageing practice owners. Deals were structured with 70–80% cash upfront and 20–30% deferred vendor payments over two to four years. Selling vets typically signed five-year Business Associate employment agreements, keeping clinical talent and client relationships in place. The platform deals were scrip transactions: vendors took Greencross shares, aligning them with the combined group's success.
Vet practices were bought consistently at 3.5–4.5× EBIT. Because Greencross traded publicly at 8–20× earnings, every deal was immediately EPS accretive, often within a year. The platform deals were priced higher: Mammoth at roughly 10× EBITDA (~$338m in scrip against ~$34m forecast EBITDA) and City Farmers at ~10× EBITDA ($205m against ~$20m forecast EBITDA), reflecting scale and strategic capability rather than multiple arbitrage.
Greencross targeted established companion-animal practices, typically owner-operated clinics trading for 15+ years with strong local reputations and stable client bases. The ideal seller was a vet approaching retirement with no succession plan. Early acquisitions clustered in Queensland before expanding into NSW, Victoria and South Australia.
The stated mandate was a minimum of twelve clinic acquisitions per year, funded from free cash flow and a standby acquisition facility. In practice the pace accelerated: 24 acquisitions were completed in FY12 alone. After the Mammoth merger, the mandate broadened from pure vet consolidation to building an integrated pet care platform, with new store openings (19 in FY14) running alongside continued clinic acquisitions.
Between the 2007 IPO and the 2019 delisting, Greencross completed well over 100 veterinary clinic acquisitions plus two transformational platform deals. Total identified acquisition spend exceeded $750m, dominated by the Mammoth merger (~$338m in scrip) and City Farmers ($205m). The pattern shows three phases: clinic-by-clinic roll-up (2007–2013), platform transformation (2014), and integration under competitive pressure (2015–2019).
Listed June 2007 at $1.00, raising ~$10m with 32 clinics. Practices were acquired at 3.5–4.5× EBIT, typically $0.5–3m each with 20–30% deferred. The network grew to ~70 practices across QLD, NSW and VIC, plus a 75.3% stake in the Animal Emergency Centre group.
24 acquisitions in a single year lifted the network to 86+ practices and ~9% Queensland market share. FY12 revenue reached $82.6m (up 35%) and NPAT $4.9m (up 41%). Greencross also opened its own veterinary pathology labs in Melbourne and Brisbane. An $11.2m placement funded the $5.1m Ku-Ring-Gai acquisition and further deals. The group added two crematoria, including the Greenbank Pet Cemetery & Crematorium ($1.45m).
Greencross merged with Mammoth Pet Holdings, owner of 100 Petbarn stores in Australia and 24 Animates stores in NZ (a 50:50 JV with EBOS). Greencross issued 52.6 million shares, 58.25% of the merged register, in a scrip deal valued at ~$338m (~10× EBITDA). The merged group had ~$443m revenue and ~$50m EBITDA.
It then acquired City Farmers from Quadrant Private Equity for $205m (~10× forecast EBITDA of $20m), adding 42 stores and a strong WA footprint, funded by shares to vendors plus an equity raise. The network reached 285 locations. FY14 clinic acquisitions added a further $15.6m revenue.
Focus shifted from large M&A to integration, in-store clinic co-location and organic rollout. Revenue grew from $645m (FY15) to $818m (FY17); EBITDA from $63m to $100m. TPG's $6.45 approach in 2016 was rejected as "opportunistic". From 2016 the share price slid from $9+ to under $4 as online competitors pressured the retail thesis.
TPG Capital acquired Greencross via scheme of arrangement at $5.55 per share: $675m equity value, ~$970m enterprise value (~10× FY18 EV/EBITDA). Shareholders voted 99.67% in favour. Greencross delisted in March 2019.
Greencross used a "franchise-like" integration approach. Acquired clinics kept their local identity and clinical autonomy but moved onto centralised systems for purchasing, payroll, marketing and financial reporting. Practice managers reported to group area managers, who reported to a corporate support team whose explicit job was to support front-line vets rather than direct them. Selling vets stayed on under five-year Business Associate agreements, preserving the client relationships that drive a practice's value.
The company invested in accredited facilities, upgraded equipment, flexible rosters, transparent remuneration and education programs to attract and retain vets in a talent-constrained industry. Benchmarking, Net Promoter Score programs and the Healthy Pets Plus plan drove like-for-like growth of 5.4% in revenue and 10.3% in EBIT (FY13): evidence that practices performed better inside the network than outside it. Bulk purchasing lowered the cost of drugs and consumables across the group.
The Mammoth and City Farmers deals multiplied integration complexity. Combining a healthcare services business with big-box retail required shared customer databases, co-location builds, and the management of two very different workforces. The group went from 97 locations in mid-2013 to over 400 by mid-2015. Co-location of clinics inside Petbarn stores became the central growth lever, but the operational strain contributed to margin pressure, leadership turnover (three CEOs between 2014 and 2018), and ultimately to the market's loss of confidence in the listed structure.
Greencross paid fully franked dividends from FY14, once the merged group had the scale to support distributions, including a final fully franked dividend of up to $0.21 per share paid as part of the TPG scheme consideration. The bulk of shareholder returns, however, came from capital growth.
The share price told a story of two halves. From the $1.00 IPO, consistent EPS-accretive clinic acquisitions carried the stock to ~$2.30 by 2012 and above $6.00 after the Mammoth merger. The integrated model and City Farmers deal drove a peak above $9.00 in 2016. From there, concerns about Pet Circle and Amazon, margin pressure and management churn cut the price to ~$3.84 (one-month VWAP) by October 2018. TPG's $5.55 offer (14% below its own rejected 2016 bid of $6.45) was accepted almost unanimously.
Chart (bubbles): Greencross share price at key points
Source: Deal Advisory analysis. "After Mammoth" and "2016 peak" show the levels the shares traded above.
The verdict on acquisitions and the share price: clinic acquisitions clearly improved it, as every deal was accretive and the market paid for the growth. The platform deals created value initially (the stock tripled) but added a retail exposure the market later repriced sharply when online disruption arrived. Acquisitions built the company; the retail acquisition mix determined where the share price ended.
In November 2018, Greencross entered a scheme implementation agreement with Vermont Aus Pty Ltd, an entity of TPG Capital Asia and TPG Growth, at $5.55 per share. That implied $675m of equity value and ~$970m enterprise value: about 10× FY18 EV/EBITDA, ~1.1× EV/revenue and ~18× earnings.
TPG was proven right quickly. Pet ownership boomed through COVID-19, and by FY25 Greencross was generating ~$2bn in revenue and over $400m in EBITDA across roughly 247 Petbarn stores and 143 vet clinics. In 2022, TPG sold a 45% stake to AustralianSuper and HOOPP at a ~$3.5bn valuation, roughly five times the 2019 equity value in three years.
The exit since has proven harder. A $3.75bn sale to EBOS collapsed in late 2023, Wesfarmers looked and passed, a planned ~$700m IPO at a ~$4bn valuation was shelved in early 2026, and in July 2026 Coles walked away from a ~$4bn acquisition after two weeks of public due diligence, citing investor backlash and a softening pet care outlook.
Four failed processes at the same price mark suggest TPG's ask sits above what buyers will currently pay. But even at the 2022 stake-sale valuation, its returns remain exceptional.
Greencross's core engine was simple: buy vet clinics at 3.5–4.5× EBIT while the public market valued the consolidated earnings at 8–20×. Every acquisition was EPS accretive, often within a year.
This only works where thousands of small, owner-operated businesses have no natural buyer. The Australian vet market of the 2000s was exactly that, and Greencross was first to it at scale.
The founder's industry credibility mattered. As a practising vet, Richards knew which practices to buy, what to pay and how to win over sellers. He sold succession, not just price.
The Mammoth merger tripled the share price in two years and created a genuinely differentiated business. Strategically, it was right: vets plus retail plus loyalty data was a model competitors could not easily copy.
But it also bolted a lower-margin, disruption-exposed retail business onto a defensive healthcare one. Going from 97 to 400+ locations in two years stretched management, compressed margins and churned three CEOs in four years.
Lesson: a transformational deal changes what the company is. Integrate fully before the next one, and be honest about which part of the new business the market will reprice in a downturn.
The market cut Greencross from $9+ to under $4 on fears about Amazon and Pet Circle, fears that applied to perhaps half the business. The vet network (you cannot vaccinate a dog online) was repriced along with retail.
TPG paid $5.55, and three years later the business was worth ~5× more. The assets had not changed; the owner's time horizon had.
Lesson: integrated roll-ups get valued on their weakest segment in a panic. For acquirers, that is precisely when to buy. The best returns in this story went to the buyer who arrived after the public market gave up.
The 2007–2013 vet roll-up is close to a textbook execution: disciplined pricing, vendor alignment through deferred payments and employment agreements, genuine operational improvement (10%+ like-for-like EBIT growth), and a dozen-plus deals a year without losing control. The Mammoth merger was strategically sound and initially rewarded with a tripled share price.
Partially. Roughly 60% of Australian vet practices remain independent, but corporate consolidators (VetPartners, Apiam, Greencross itself) now compete for targets, and entry multiples have risen from 4× EBIT to 6–10× EBITDA. The pure arbitrage is gone.
A new entrant needs an angle: regional clinics, emergency and specialist care, or an operating capability that lifts clinic earnings enough to justify today's prices. The 2007 playbook no longer works at 2026 prices; a version of it still can.
Get a free, data-backed estimate of what your business could be worth.
Get your free appraisal
